DrugPatentWatch Database Preview
ADVAIR DISKUS 250/50 Drug Profile
Email this page to a colleague
See Plans and PricingWhen do Advair Diskus 250/50 patents expire, and what generic alternatives are available?
Advair Diskus 250/50 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.
The generic ingredient in ADVAIR DISKUS 250/50 is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.
Summary for ADVAIR DISKUS 250/50
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 5 |
| Clinical Trials: | 48 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ADVAIR DISKUS 250/50 at DailyMed |
Recent Clinical Trials for ADVAIR DISKUS 250/50
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| BECRO Ltd. | Phase 1 |
| Respirent Pharmaceuticals Co Ltd. | Phase 1 |
| Teva Pharmaceuticals USA | Phase 3 |
Pharmacology for ADVAIR DISKUS 250/50
| Drug Class | beta2-Adrenergic Agonist Corticosteroid |
| Mechanism of Action | Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for ADVAIR DISKUS 250/50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | ADVAIR DISKUS 250/50 | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 021077-002 | Aug 24, 2000 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
